$3.07
+1.66%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.97
From 52W high−40.96%
Volume85270.00
Market cap$14.87M
P/E (TTM)—
P/S (TTM)3290.7x
Div yield—
Key dataOct 19, 2026
Open
$2.97
From 52W high
−40.96%
Volume
85270.00
Market cap
$14.87M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
42.2
MomentumView details →
1D Return
+1.66%
YTD Return
+0.17%
SummaryUpdated Jul 1, 2026
Heart Test Laboratories, Inc. (NASDAQ:HSCS) is a medical technology company founded in 2007 and headquartered in Southlake, Texas. The company went public in June 2022, focusing on developing and commercializing advanced cardiovascular diagnostic devices. Heart Test Laboratories represents an early-stage medical device company attempting to bring innovative electrocardiography technology to market, though it has faced significant challenges in generating meaningful revenue since its public debut.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted 510(k) clearance (K260005) to HeartSciences Inc. for its MyoVista wavECG device as a 12-lead resting electrocardiograph for adult and pediatric patients.13d agoHeartSciences Inc. amended its loan and security agreement with Front Range Ventures LLC, extending the loan maturity to the earlier of two business days after closing a proposed business combination with Fortitude Mining Holdings, Inc. or January 29, 2027.17d agoHeartSciences reported that its proposed business combination with Fortitude, a vertically-integrated digital asset mining platform anchored in Zcash, continues to progress, with closing expected in the fourth quarter of calendar 2026.34d ago